Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

AstraZeneca PLC (NASDAQ:AZN | AZN Price Prediction) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date, the stock has gained 6.02%, though it has pulled back nearly 5% over the past month from a 52-week high of $212.71.

Most Wall Street analysts carry a consensus price target of $208.54 on the U.S.-listed ADR. Guggenheim analyst Seamus Fernandez, however, just raised his firm’s price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm’s model ahead of Q1 earnings. Here is what it would take for AZN to reach 16,500 GBp by the end of 2026.

Seamus Fernandez’s 16,500 GBp AZN Prediction

Fernandez’s upgrade follows a model refresh timed to AstraZeneca’s Q1 2026 earnings report, expected May 1. The revision reflects confidence in the company’s execution after FY2025 total revenue of $58.74 billion, up 8% at constant exchange rates, and management’s guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth in 2026. With 8 buy-equivalent ratings and only 1 strong sell among tracked analysts, Guggenheim’s call sits at the optimistic end of an already constructive Street consensus.

Key Drivers of AZN Stock Performance

1. Oncology momentum: The oncology segment generated $25.618 billion in FY2025 revenue, up 17% CER, anchored by Tagrisso at $7.254 billion and Enhertu at $2.775 billion, up 40% CER. This diversified blockbuster portfolio has delivered consistent revenue growth across multiple years.
2. Pipeline depth: AstraZeneca recorded 16 positive Phase 3 readouts and 43 regulatory approvals in 2025, with 20+ Phase 3 trial readouts expected in 2026 and obesity candidate elecoglipron advancing to Phase III. Each approval represents a potential new revenue stream for the company.
3. Capital returns and reinvestment: The company raised its dividend to $3.30 per share for 2026 while committing to a roughly one-third increase in capital expenditures, alongside a $15 billion China investment through 2030. This combination of income and reinvestment signals management confidence in long-term growth.

What Will It Take for AZN to Reach 16,500 GBp?

AstraZeneca carries a current market cap of approximately $292.1 billion with 1.55 billion shares outstanding. Reaching the Guggenheim target would require sustained execution on the 2026 revenue and EPS growth guidance, continued oncology market share gains, and at least one meaningful pipeline catalyst from the dense Phase 3 readout calendar. A forward P/E of 18.08x leaves room for multiple expansion if core EPS growth accelerates as guided.

The primary risk is pipeline disappointment or currency headwinds compressing CER growth into reported figures. Even so, Guggenheim’s refreshed 16,500 GBp target reflects a disciplined, earnings-driven case built on AstraZeneca’s execution track record and pipeline depth.